menu
    • menu
    [{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2025","type":"Series A Financing","leadProduct":"HTX-001","moa":"IncRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"HAYA Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"HAYA Therapeutics \/ Sofinnova Partners","highestDevelopmentStatusID":"5","companyTruncated":"HAYA Therapeutics \/ Sofinnova Partners"},{"orgOrder":0,"company":"DiNAQOR AG","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"DiNA-001","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"DiNAQOR AG","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiNAQOR AG \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"DiNAQOR AG \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"Inositec AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INS-3001","moa":"Vascular calcification","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inositec AG","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inositec AG \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Inositec AG \/ Undisclosed"},{"orgOrder":0,"company":"Inositec AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INS-3001","moa":"Vascular calcification","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inositec AG","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inositec AG \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Inositec AG \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HAYA Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HAYA Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HTX-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : Sofinnova Partners

                            Deal Size : $65.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            HAYA Therapeutics Raises $65M Series A for RNA-Guided Chronic Disease Drugs

                            Details : The funds will used to advance clinical development of ASO heart failure lead candidate HTX-001, which is being evaluated for the treatment of non-obstructive hypertrophic cardiomyopathy.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            May 08, 2025

                            Lead Product(s) : HTX-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Sofinnova Partners

                            Deal Size : $65.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Inositec AG

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Inositec AG

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INS-3001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001

                            Details : U.S. patent number covers specifically the composition of matter and use of inositol derivatives for conditions related to pathological calcium crystallization.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 04, 2020

                            Lead Product(s) : INS-3001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DiNAQOR AG

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            DiNAQOR AG

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DiNA-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : BioMarin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement

                            Details : The license initially covers DiNAQOR's lead program, DiNA-001 for MYBPC3 hypertrophic cardiomyopathy. Additionally, the companies will collaborate on several of DiNAQOR's other pipeline programs.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 03, 2020

                            Lead Product(s) : DiNA-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : BioMarin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth